This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

September 20–23, 2021
Proudly part of Biotech Week BostonDelivered Digitally | US Eastern Daylight Time

Kendra Rose
VP and Head of New Business Development at Bayer Healthcare


Kendra Rose, PhD, MBA, is Vice President and Head of New Business Development within the Pharmaceuticals Business Development & Licensing team at Bayer. With her unique career experience, she brings insight from multiple facets including commercial evaluation, product launches, and research and development.

In this capacity, her responsibilities include developing valuation models and providing commercial input and evaluation for all pharmaceutical deals. She had leadership roles in recent key acquisitions, such as Asklepios BioPharmaceutical, Inc. (AskBio) and Vividion Therapeutics. Working across multiple therapeutic areas internally and externally, Kendra and her team constantly re-evaluate and evolve Bayer Pharmaceuticals’ approach to partnering.

Kendra joined Bayer in 2015 and has worked in new products in different therapeutic areas, with responsibilities for commercial input for the internal and external pipeline. In particular, she prepared the commercialization of recent late-stage Cardiovascular assets, which are in the process of launching globally, while simultaneously driving the Cardiovascular strategy.

Prior to joining Bayer, she worked at Novartis in Global New Products and led the global launch for a heart failure drug. Kendra started her career at Johnson & Johnson Consumer Products in R&D and went on to work in various roles for US marketing in its medical device sector and later in a cross-sector Innovation role.

Kendra holds a PhD in Chemistry from Stanford University and an MBA from The Wharton School, University of Pennsylvania.

Agenda Sessions

  • Dealmaker insights